**EGR1 expression: a calcium and ERK1/2 mediated
PPAR-independent event involved in the
antiproliferative effect of 15-deoxy-(12,14-prostaglandin
J2 and Thiazolidinediones in breast cancer cells**

Sarra Chbicheb, Xiao Yao, Jean-Luc Rodeau, Stéphane Salamone, Michel
Boisbrun, Gerald Thiel, Daniel Spohn, Isabelle Grillier-Vuissoz, Yves
Chapleur, Stéphane Flament, et al.

► **To cite this version:**

Sarra Chbicheb, Xiao Yao, Jean-Luc Rodeau, Stéphane Salamone, Michel Boisbrun, et al.. EGR1 expression: a calcium and ERK1/2 mediated PPAR-independent event involved in the antiproliferative effect of 15-deoxy-(12,14-prostaglandin J2 and Thiazolidinediones in breast cancer cells. *Biochemical Pharmacology*, 2011, 81 (9), pp.1087. 10.1016/j.bcp.2011.02.006 . hal-00685074

HAL Id: hal-00685074

<https://hal.science/hal-00685074>

Submitted on 4 Apr 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: EGR1 expression: a calcium and ERK1/2 mediated PPAR_γ-independent event involved in the antiproliferative effect of 15-deoxy-(12,14-prostaglandin J2 and Thiazolidinediones in breast cancer cells

Authors: Sarra Chbicheb, Xiao Yao, Jean-Luc Rodeau, Stéphane Salamone, Michel Boisbrun, Gerald Thiel, Daniel Spohn, Isabelle Grillier-Vuissoz, Yves Chapleur, Stéphane Flament, Sabine Mazerbourg

PII: S0006-2952(11)00110-9
DOI: doi:10.1016/j.bcp.2011.02.006
Reference: BCP 10827

To appear in: *BCP*

Received date: 26-11-2010
Revised date: 10-2-2011
Accepted date: 11-2-2011

Please cite this article as: Chbicheb S, Yao X, Rodeau J-L, Salamone S, Boisbrun M, Thiel G, Spohn D, Grillier-Vuissoz I, Chapleur Y, Flament S, Mazerbourg S, EGR1 expression: a calcium and ERK1/2 mediated PPAR_γ-independent event involved in the antiproliferative effect of 15-deoxy-(12,14-prostaglandin J2 and Thiazolidinediones in breast cancer cells, *Biochemical Pharmacology* (2010), doi:10.1016/j.bcp.2011.02.006

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**EGR1 EXPRESSION : A CALCIUM AND ERK1/2 MEDIATED PPAR γ -
INDEPENDENT EVENT INVOLVED IN THE ANTIPROLIFERATIVE EFFECT OF
15-DEOXY- Δ 12,14-PROSTAGLANDIN J2 AND THIAZOLIDINEDIONES IN
BREAST CANCER CELLS**

**Sarra Chbicheb^a, Xiao Yao^a, Jean-Luc Rodeau^b, Stéphane Salamone^{c1}, Michel Boisbrun^c,
Gerald Thiel^d, Daniel Spohn^d, Isabelle Grillier-Vuissoz^a, Yves Chapleur^c, Stéphane Flament^a,
and Sabine Mazerbourg^a**

^aEA 4421 Signalisation, Génomique et Recherche Translationnelle en Oncologie (SIGRETO) Nancy-
Université, 54506 Vandœuvre-lès-Nancy, France
SC: sarra.chbicheb@scbiol.uhp-nancy.fr; SF: stephane.Flament@scbiol.uhp-nancy.fr; IGV:
isabelle.grillier-vuissoz@scbiol.uhp-nancy.fr; SM:sabine.mazerbourg@scbiol.uhp-nancy.fr;
XY: dawnnyao@yahoo.com

^bInstitut des Neurosciences Cellulaires et Intégratives (INCI) CNRS UPR-3212 67084 Strasbourg,
France
JLR : jlr@inci-cnrs.unistra.fr

^cGroupe S.U.C.R.E.S., UMR 7565 CNRS, Nancy-Université, 54506 Vandœuvre-lès-Nancy, France
MB : Michel.Boisbrun@pharma.uhp-nancy.fr; YC: yves.chapleur@sucres.uhp-nancy.fr; SS:
stephane.salamone@pasteur.fr

^dDepartment of Medical Biochemistry and Molecular Biology, University of Saarland Medical Center,
D-66421 Homburg, Germany (G.T., D.S.)
GT: gerald.thiel@uniklinik-saarland.de; DS: daniel.spohn@uniklinik-saarland.de

Corresponding author: Sabine Mazerbourg, EA 4421 Signalisation, Génomique et Recherche
Translationnelle en Oncologie (SIGRETO), Université Henri Poincaré, Nancy-Université, Faculté des
Sciences, BP 70239, 54506 Vandœuvre-lès-Nancy; Cedex France. Tél : 011 33(0) 3 83 68 42 57, Fax :
011 33(0) 3 83 68 40 01; E-mail: sabine.mazerbourg@scbiol.uhp-nancy.fr

Abstract

Our aim was to get new information about the Peroxisome Proliferator Activated Receptor gamma (PPAR γ)-independent pathway involved in the antiproliferative action of PPAR γ ligands in breast cancer cells. We investigated the effects of Troglitazone (TGZ), Ciglitazone (CGZ), Rosiglitazone (RGZ) and, 15-deoxy- Δ 12,14-prostaglandin J2 (15d-PGJ₂) on the hormone-dependent breast cancer cell line MCF7. The early transcription factor *EGR1* (Early Growth Response gene 1) mRNA and protein levels peaked after 3 hours of incubation with 25 μ M TGZ, CGZ or 15d-PGJ₂ and then gradually decreased. RGZ, the most potent activator of PPAR γ , did not show this effect. The PPAR γ antagonist GW 9662 did not block *EGR1* mRNA induction which also still occurred in case of PPAR γ silencing as well as in case of treatment with the PPAR γ -inactive compound Δ 2-TGZ. *EGR1* mRNA induction required ERK1/2 phosphorylation which was not blocked by EGF Receptor (EGFR) inhibition. The ERK1/2 pathway was also involved in Δ 2-TGZ-induced *EGR1* mRNA expression in the hormone-independent breast cancer cell line MDA-MB-231. Using the fluorescent dye Fura2, we showed in MCF7 that TGZ or Δ 2-TGZ induced an immediate increase in cytosolic calcium which was required for ERK1/2 phosphorylation and *EGR1* mRNA induction as demonstrated by calcium chelation experiments. Furthermore, in MCF7 transfected with siRNA targeting *EGR1*, Δ 2-TGZ inhibited less efficiently cell proliferation.

Graphical abstract : Troglitazone (TGZ) and Δ 2-TGZ induce an increase in cytosolic calcium leading to ERK1/2 phosphorylation and *EGR1* expression in breast cancer cells, leading to growth inhibition. This event is independent of PPAR γ and EGFR activation.

Keywords : Thiazolidinedione, Troglitazone, *EGR1*, calcium signaling, breast cancer

Abbreviations list:

PPAR : peroxisome proliferator-activated receptor

EGR1 : Early Growth Response gene 1

15d-PGJ₂ : 15-deoxy- Δ 12,14-prostaglandin J2

TGZ : Troglitazone

CGZ : Ciglitazone

RGZ : Rosiglitazone

EGFR : EGF Receptor

NAB : NGFI-A-binding protein

FCS : fetal calf serum

DMSO : dimethylsulfoxide

DMEM : Dulbecco's modified Eagle's medium

dNTP : desoxynucleotide triphosphate

DTT : dithiothreitol

Ig : Immunoglobulin

MAPK : mitogen activated protein kinase

RPLPO : acidic ribosomal phosphoprotein PO

1. Introduction

The peroxisome proliferator-activated receptors (PPARs) are a family of ligand-activated transcription factors belonging to the nuclear receptor superfamily [1]. Three PPAR subtypes encoded by separate genes have been identified: α , β/δ and γ . Ligands of PPAR γ include 15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂ (15d-PGJ₂), oxidative metabolites of polyunsaturated fatty acids and synthetic compounds like thiazolidinediones (troglitazone TGZ, ciglitazone CGZ, rosiglitazone RGZ...), a class of drugs used in the treatment of type II diabetes [2]. Various PPAR γ agonists have anti-cancer activities [3, 4]. For instance, TGZ and 15d-PGJ₂ inhibit tumor growth of human prostate, colorectal or breast cancer cells in immunodeficient mice [4]. Anticancer effects of such compounds have also been observed *in vitro*. For example, in breast cancer cell lines, they inhibit proliferation, induce differentiation or trigger apoptosis [5, 6]. Recently, a nonapoptotic and nonautophagic cytoplasmic vacuolation death was observed in response to 15d-PGJ₂ whereas autophagy was described in response to thiazolidinediones in the same breast cancer cell line MDA-MB-231 [7, 8].

Several data suggest that the anticancer effects of PPAR γ ligands could be the result of PPAR γ -independent events [9]. This was deduced from studies using PPAR γ antagonists, transfection of dominant negative PPAR γ isoforms, PPAR γ -targeted RNA interference as well as thiazolidinedione derivatives like Δ^2 -TGZ that could not activate PPAR γ . The proteasomal degradation of estrogen receptor alpha and cyclin D1 is an example of such a PPAR γ -independent effect triggered by several PPAR γ ligands which has been well described in breast cancer cells [10-12]. However, in these cells, few data are available on the identity of mediators involved in the PPAR γ -independent pathway activated by thiazolidinediones. Interestingly, in human colon cancer cells, Early growth response gene 1 (EGR1) was

identified as an early transcription factor induced after a three hour treatment with TGZ in a PPAR γ -independent manner [13].

EGR is a family of zinc-finger transcription factors (EGR1-4) with an aminoterminal activation domain, a central domain that interacts with the co-repressors NGFI-A-binding proteins 1 and 2 (NAB1 and NAB2) (except for EGR4), and a DNA binding domain consisting of three Cys2-His2 zinc fingers near the carboxy-terminal end of the protein sequence. They are described as early response genes because they are rapidly and transiently induced [14]. EGR proteins bind the consensus nucleotide sequence GCGGGGGCG to regulate expression of target genes [15]. EGR1, (also known as NGF-1A, KROX24, ZIF268, and TIS8) is a nuclear phosphoprotein that has been reported to be rapidly induced by serum, growth factors, ultraviolet light, ionizing radiations, mechanical injury, and stress. Thus, EGR1 is involved in a variety of cell processes including growth, differentiation, angiogenesis, wound healing and apoptosis. In prostate cancer cells and few other models, EGR1 is described as a protumoral factor contributing to regulation of genes which are critical for cell cycle progression and counteracting apoptosis [16]. In contrast, EGR1 expression is absent or very weak not only in several human breast cancer cell lines compared to immortalized normal human mammary cell lines (MCF10A and 184A1N4), but also in breast cancer tissues compared to normal breast tissue [17, 18]. Moreover, induced-overexpression of EGR1 negatively regulates the growth of the breast cancer cell line ZR75 [19]. These findings suggest that in breast cancer cells and tissues, reduced expression of EGR1 could enhance tumorigenesis while EGR1 overexpression could be linked to growth inhibition.

In an effort to better understand the intracellular mode of action of thiazolidinediones, the aim of our study was 1) to determine if the potential growth inhibitor EGR1 could be an

1 element of their signaling in breast cancer cells, 2) to evaluate the role of the nuclear receptors
2 PPAR γ in this process and 3) to characterize the cellular and molecular events leading to this
3 response. Our studies performed in the hormone-dependent cell line MCF7 show that TGZ,
4 CGZ and 15d-PGJ₂ induce the early expression of EGR1 in a PPAR γ -independent manner. In
5 contrast, RGZ, the most potent PPAR γ agonist, did not stimulate EGR1 expression. EGR1
6 induction was associated with ERK activation but the transactivation of EGFR was not
7 involved. Similar results were observed in the hormone-independent breast cancer cell line
8 MDA-MB-231. Furthermore, an early increase in cytosolic calcium appeared to be a key
9 actor in the signaling pathway leading to *EGR1* expression. Finally, siRNA experiments
10 demonstrated that EGR1 was as a mediator of the inhibition of proliferation triggered by Δ 2-
11 TGZ in MCF7 cells.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

2. Materials and Methods

2.1. Cell culture and reagents

MCF7 and MDA-MB-231 human breast cancer cell lines were obtained from American Type Culture Collection (Rockville, MD, USA). Both cell lines were grown at 37°C under 5% CO₂ in phenol red Dulbecco's modified Eagle medium (DMEM, Invitrogen, Cergy Pontoise, France) for MCF-7 and in L-15 medium (Invitrogen) for MDA-MB-231. These media were supplemented with 10% fetal calf serum (FCS) (Sigma-Aldrich, Lyon, France) and 2 mM L-glutamine (Invitrogen).

TGZ, AG1478, A23187 ionophore (Sigma-Aldrich), CGZ, RGZ, GW9662, U0126, PD153035, SP600125, SB203580, BAPTA-AM (Calbiochem Merck, Darmstadt, Germany), 15d-PGJ₂ (Interchim, Montluçon, France) were dissolved in dimethylsulfoxide (DMSO; Sigma-Aldrich). Recombinant human Epidermal Growth Factor (EGF) (Invitrogen) was resuspended in PBS. The synthesis of Δ^2 -TGZ was achieved according to slight modifications of known procedures [17, 20]. Experimental details will be published elsewhere. The identity and purity of this synthetic derivative were verified by proton nuclear magnetic resonance and elemental analysis. This compound was also dissolved in DMSO.

2.2. Cell treatment

After seeding and 24 hours of incubation to allow for cell attachment, cells were washed with PBS and the medium was replaced with phenol red-free DMEM (MCF7) or L-15 medium (MDA-MB-231) supplemented with 1% FCS and 2 mM L-glutamine. After 24 hours, cells were washed with PBS and treated with either DMSO, 15d-PGJ₂, thiazolidinediones, EGF, or the calcium ionophore A23187 at the indicated concentrations and times in phenol red-free, FCS-free DMEM for MCF7 or 1% FCS L-15 medium for MDA-MB-231 supplemented with 2 mM L-glutamine. To test the involvement of the MAPK and calcium pathways or the PPAR γ and EGF receptors, cells were treated with different inhibitors for 30

minutes prior to PPAR γ ligands exposure. Cells were then collected for RNA or protein extraction.

2.3. Semi-quantitative RT-PCR

Cells were seeded in 6-well plates at a density of 5×10^5 cells/well (MCF7 cells) or 4×10^5 cells/well (MDA-MB-231 cells) in 2 mL of medium with 10% FCS and 2 mM L-glutamine. Cells were treated as previously described. Total RNA was extracted using TRIZOL reagent (Invitrogen) according to the manufacturer's instructions. cDNA was synthesized in 25 μ L volume containing 1 μ g RNA, 12 ng random hexamer primer, 1X Invitrogen Buffer, 4 mM DTT, 0.1 mM of each dNTP, 4 U RNase inhibitor and 75 U of MMLV reverse transcriptase (Invitrogen). The mixture was incubated for 10 minutes at 25°C, for 110 minutes at 37°C and subsequently for 10 minutes at 70°C in order to stop the reaction. The cDNA were further amplified by PCR. The specific primer sequences are as follows:

EGR1 (NM_001964) forward 5'-GGCCACCTCCTCTCTCTCTT-3', reverse 5'-TGTTGGCCAATAGACCTTCC-3'; *PPAR γ* (NM_138712) forward 5'-GACCACTCCCACTCCTTT-3', reverse 5'-CGACATTCAATTGCCATGAG-3'; *EGFR* (NM_005228) forward 5'-AAGCTCACGCAGTTGGGCAC-3', reverse 5'-GGTTCTGGAAGTCCATCGAC-3'; *NAB2* (NM_005967) forward 5'-GACCCTGCAGCCCAGACTC-3', reverse 5'-CTTCGATAGTGGTGACGGACC-3'; *RPLPO* (NM_053275) forward 5'-ACAACCCAGCTCTGGAGAAA-3', reverse 5'-TCGTTTGTACCCGTTGATGA-3'. PCR was carried out in a thermal cycler (Eppendorf, Le Pecq, France) in a final volume of 25 μ L containing 2 μ L cDNA, 1X EconoTaq™ Reaction Buffer (-Mg), 1.5 mM MgCl₂, 0.2 mM of dNTP mix, 0.2 μ M of each primer and 2.5 U EconoTaq. Negative controls were always included. Amplification was carried out under the following conditions: (1) initial denaturation 94°C for 2 minutes; (2) 94°C for 30 s, 58°C for

30s and 72°C for 45s. 30 PCR cycles were performed for gene amplification, with the exception of RPLPO amplified with 25 cycles. (3) 10 minutes extension step at 72°C. The number of cycles was chosen to realize the analysis in the linear phase of the PCR reaction. 20 µL of the PCR products were mixed with loading buffer (5 µl) and submitted to electrophoresis in a 1.2 % agarose gel at 90 V for 35 minutes at room temperature. The gel was stained with ethidium bromide, viewed and photographed on a UV-transilluminator (GelDoc 2000, Bio-Rad Laboratories, Marnes-La-Coquette, France). A software package (Quantity One v.4.3.1, Bio-Rad Laboratories) was used to quantify the PCR products.

2.4. RNA interference

The small-interfering RNA (siRNA) duplexes for targeting PPAR γ , EGR1 and EGFR as well as a scrambled sequence (control siRNA duplex, negative control) were purchased from Eurogentec (Angers, France). The sequences are shown in Table 1. MCF7 cells (1.45 x 10⁵) were plated overnight in twelve-well culture plates in DMEM supplemented with 10% FCS and 2 mM L-glutamine. Cells were transiently transfected with either target gene siRNA (200 nM of the mix duplex 1 and duplex 2 or 200nM of one duplex) or negative control siRNA-sequence (Table 1) using the Oligofectamine™ Reagent (Invitrogen) as described by the manufacturer. The concentration of siRNA used was standardized to get maximum knockdown without affecting the viability of the cells. After 24 hours, cells were washed with PBS and the medium was replaced with phenol red-free DMEM supplemented with 1% FCS and 2 mM L-glutamine. 24 hours later, cells were treated in phenol red-free and FCS-free DMEM with 2 mM L-glutamine and harvested for further analyses.

2.5. Nuclear protein extracts

At the end of the treatment, cells were washed twice with cold PBS and collected in 1 mL PBS. Nuclear and cytoplasmic extracts were prepared by detergent lysis. Briefly, after pelleting, the cells were incubated in hypotonic solution (10 mM Hepes-KOH, pH 7.9, 1.5 mM MgCl₂, 10 mM KCl, 0.5 mM dithiothreitol (DTT), 0.5% Nonidet P40, 2.5X Protease inhibitor cocktail tablet, Roche) for 15 minutes on ice and vortexed each 5 minutes. Nuclei were collected by centrifugation at 13 000 rpm for 5 minutes at 4°C. The nuclei pellet was then resuspended in a hypertonic buffer (10 mM Hepes-KOH pH 7.9, 25% Glycerol, 420 mM NaCl, 1.5 mM MgCl₂, 0.2 mM EDTA, 0.5 mM DTT, 0.5% Triton, 2.5X Protease inhibitor cocktail tablet, Roche, Fontenay sous Bois, France). Nuclei were incubated for 15 minutes at 4°C with shaking. After centrifugation (13 000 rpm, 5 minutes, 4°C), the supernatant containing nuclear proteins was stored at -80°C. Protein concentrations were determined by the Bradford method (Bio-Rad Protein Assay, Bio-Rad Laboratories).

2.6. Western immunoblotting

For EGR1 detection, 30 µg of nuclear proteins were mixed with 2X Laemmli buffer, boiled (100°C, 5 minutes) and separated by 10% SDS-PAGE. For other protein analyses, cells were harvested by addition of 150 µL 2X Laemmli buffer and boiled. For each sample, 30 µL of total proteins were separated by 10% SDS-PAGE. After electrophoresis, proteins were transferred onto nitrocellulose membrane. The homogeneity of loaded amounts and transfer efficiency were confirmed by Ponceau S staining of nitrocellulose membranes for each experiment. Non specific binding sites were blocked in TNT buffer (5 mM Tris-HCl, 15 mM NaCl, 0.1% Tween 20) with 5% non-fat powder milk and incubated with the primary antibodies diluted in blocking solution overnight at 4°C. The rabbit monoclonal antibodies anti-EGR1 (SC-189, Santa Cruz Biotechnology, USA) and anti-phospho-p44/42 MAPK

(ERK1/2) (Thr 202/Tyr 204) (Cell Signaling Technology/Ozyme, Saint-Quentin en Yvelines, France) were diluted at 1:1000. Total ERKs were detected using a rabbit monoclonal anti-p44/42 MAPK (ERK1/2) antibody (Cell Signaling Technology) at 1:5000 in blocking solution. The rabbit polyclonal antibody anti-actin was used diluted at 1:3000.

Next, the membranes were washed 3 times with TNT and incubated for 2 hours with a peroxidase-linked secondary antibody (Santa Cruz Technology) at room temperature. After 3 washings with TNT, the membranes were developed with ECL detection reagent using chemiluminescence (Amersham, Orsay, France). After Phospho-p44/42 MAPK analysis, the blots were stripped and reprobed with anti-p44/42 MAPK antibody.

2.7. Immunocytochemistry

MCF7 cells (1.45×10^5) were seeded on glass coverslips and grown in their medium as described before. Cells were treated with TGZ or DMSO for 3 hours in phenol red-free DMEM containing 1% FCS. At the end of treatment, coverslips were washed with PBS and fixed in 4% paraformaldehyde (Sigma-Aldrich) for 15 minutes. After washing in PBS, preparations were permeabilized for 10 minutes in 0.5% Triton X100. After washing in PBS, non specific binding was blocked by incubation for 30 minutes in a blocking solution (4% bovine serum albumin, 0.1% Triton X100 in PBS Buffer). Samples were incubated with the anti-EGR1 antibody (SC-189, Santa Cruz Biotechnology) diluted at 1:400 in the blocking solution for 1 hour. They were then washed 3 times in the blocking solution and exposed for 1 hour to Alexa Fluor 555 goat anti-mouse IgG antibody (Invitrogen) diluted 1:1000 in the blocking solution. Finally, cells were rinsed with PBS 0.1% Triton X100 for 15 minutes and cells were counterstained with Hoechst dye to visualize nuclei. Fluorescence labelling was observed under an Eclipse 80i microscope (Nikon, Champigny sur Marne, France). Images were collected using LuciaG software 4.81 (Laboratory imaging/Nikon).

2.8. Intracellular calcium imaging

MCF7 cells were seeded on glass coverslips as described above. The cytoplasmic Ca^{2+} concentration was detected by the ratiometric fluorescent probe Fura-2. Cells were loaded with 5 μM of the cell-permeant precursor Fura-2 acetoxymethyl ester (Fura-2/AM; Molecular Probes Invitrogen) in presence of pluronic F-127. After 1 hour incubation, they were washed three times with the recording saline solution containing (in mM): NaCl, 120; KCl, 5; CaCl_2 , 2; MgCl_2 , 2; D-glucose, 10; and Hepes, 20; pH 7.3. Fluorescence measurements were performed on an inverted microscope (Axiovert 35; Zeiss, Germany) with an oil-immersion $\times 40$ Nikon objective (Fluor 40, NA 1.30) and a cooled CCD camera (CoolSnap HQ; Photometrics, USA). The Imaging Workbench 4.0 software (Axon Instruments, USA) was used for image acquisition and analysis. Fluorescence was excited alternately at 350 and 380 nm with a Lambda-10 filter wheel (Sutter Instrument, USA), and emitted light was collected above 520 nm. Pairs of images were acquired every 2 seconds. Intracellular calcium was expressed throughout as the fluorescence ratio F_{350} / F_{380} , calculated after background subtraction. Experiments were performed at room temperature (25-30°C). During calcium measurements, the cells were continuously superfused with saline solution: the whole dish by a bath perfusion of control medium and the recorded field by a single-tip multichannel gravity-fed system, allowing switching between various solutions. All drugs were prepared at the indicated concentrations in saline solution.

2.9. Cell proliferation assay

48 h after siRNA transfection, the medium was replaced by DMEM supplemented with 1% FCS and 2 mM L-glutamine. After 4h, cells were treated for 24 h with 15 μM $\Delta 2$ -

1 TGZ in DMEM supplemented with 0% FCS and 2 mM L-glutamine. Control wells received
2 0.05% DMSO. At the end of the treatment, cells were washed with PBS, trypsinized and
3
4 counted with the CellTiter-GloTM Luminescent Cell Viability Assay (Promega, Charbonnières,
5
6 France). Each treatment was performed five times.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

3. Results

3.1. Troglitazone induces early EGR1 expression in MCF7 breast cancer cells

Exposure of the estrogen-dependent human breast cancer epithelial cell line MCF7 to 25 μ M TGZ induced a transient expression of *EGR1* mRNA which appeared at 30 minutes, peaked at 3 hours and then decreased (Fig. 1A). The vehicle DMSO (0.05%) did not induce a significant increase in *EGR1* mRNA expression compared to the non-treated sample (Fig. 1A). Furthermore, TGZ stimulated *EGR1* mRNA expression in a dose-dependent manner with a better response observed at 25 μ M than 5 μ M (Fig. 1B). At the protein level, EGR1 was also stimulated with a maximum in nuclear extracts of cells that had been exposed to 25 μ M TGZ for 3 hours (Fig. 1C). Fetal calf serum (FCS) used as a positive control induced a higher and earlier stimulation of EGR1 (Fig. 1C). Ponceau S protein staining of membranes after transfer confirmed equivalence of loaded samples (not shown). In immunocytochemistry experiments, we observed a nuclear staining with the anti-EGR1 antibody in cells exposed for 3 hours to 25 μ M TGZ. However, all the cells did not display the same staining intensity which varies from faint to intense (Fig 1D). In MCF7 cells exposed for 3 hours to 20% FCS, the nuclear staining intensities were higher, that was in accordance with the results of western blot analyses. Staining intensity was not homogeneous between cells, as previously described.

In order to confirm the activation of the EGR1 pathway in cells exposed to TGZ, we analyzed the EGR1 target gene *NAB2*. *NAB2* mRNA was constitutively expressed in MCF7 cells (Fig. 1E). 25 μ M TGZ induced a transient expression of *NAB2* mRNA which appeared at 6 hours, peaked at 9 hours and then decreased (Fig. 1E). The vehicle DMSO (0.05%) did not induce a significant increase in *NAB2* mRNA expression compared to the non-treated sample (Fig. 1E).

3.2. EGR1 induction by troglitazone, ciglitazone and 15d-PGJ₂ is PPAR γ -independent

Other PPAR γ ligands were tested. Both CGZ and 15d-PGJ₂ (25 μ M) were able to induce a transient expression of *EGR1* mRNA with a peak of expression observed after 3 hours of treatment (Fig. 2A). The transcription of *EGR1* was followed by translation of EGR1 and by *NAB2* stimulation (Fig. 2B and C). In contrast, these events were not observed after 25 μ M RGZ treatment (Fig. 2A-B). Since RGZ is a more potent PPAR γ agonist than TGZ, CGZ or 15d-PGJ₂, it suggested that the induction of *EGR1* expression required a PPAR γ -independent mechanism.

It was demonstrated by three different complementary approaches. In MCF7 cells co-treated for 3 hours with 25 μ M TGZ, CGZ or 15d-PGJ₂ and the irreversible PPAR γ antagonist GW9662 (5 or 25 μ M) *EGR1* mRNA expression was still stimulated (Fig. 3A). When TGZ (25 μ M) was tested on PPAR γ siRNA transfected MCF7 cells (in which PPAR γ mRNA level was decreased by more than 80%), the induction of *EGR1* mRNA expression was still induced after 3 hours of treatment (Fig. 3B). Besides, MCF7 cells that were treated for 3 hours with 25 μ M Δ 2-TGZ, a TGZ derivative devoid of PPAR γ agonist activity, displayed an increase in *EGR1* and *NAB2* mRNA levels (Fig. 3C). Such a Δ 2-TGZ treatment was also able to induce the expression of EGR1 protein (Fig. 3D).

3.3. Troglitazone, ciglitazone and 15d-PGJ₂ rapidly activate ERK1/2 pathway

We studied if the extracellular signal-regulated kinase (ERK) 1/2 pathway could be involved in EGR1 expression stimulation. TGZ, CGZ and 15d-PGJ₂ (25 μ M) induced ERK1/2 phosphorylation that could be detected as soon as 5 minutes after stimulation (Fig. 4A). The signal intensity increased between 15 and 45 minutes following treatment and decreased thereafter (Fig. 4A). In case of Δ 2-TGZ (25 μ M) treatment, ERK1/2

phosphorylation occurred more slowly: it was detected 15 minutes after stimulation and increased up to 75 minutes (Fig. 4B). In contrast to these compounds, RGZ induced no change in ERK1/2 phosphorylation (data not shown).

In MCF7 cells that were pretreated for 30 minutes with the MEK1/2 inhibitor U0126 (5 μ M) and subsequently treated with vehicle or 25 μ M TGZ, CGZ, 15d-PGJ₂ (15 minutes) and Δ 2-TGZ (30 minutes), no activated ERK1/2 was found (Fig. 4C). At a concentration as low as 5 μ M, U0126 was efficient to inhibit the *EGR1* expression usually induced by TGZ, CGZ, 15d-PGJ₂ (Fig. 4D). In case of Δ 2-TGZ treatment, U0126 inhibited *EGR1* mRNA induction partially at 5 μ M whereas a complete inhibition was observed at 25 μ M (Fig. 4D). The MAPK inhibitor was also able to inhibit the TGZ-induced increase in EGR1 protein (Fig. 4E). To determine the role of the other MAP Kinases on the regulation of *EGR1* expression, cells were treated with Δ 2-TGZ in the presence of 10 μ M of a specific inhibitor of p38 MAPK (SB203580) (Fig. 5A) and JNK (SP600125) (Fig. 5B). In contrast to U0126 that completely abolished *EGR1* expression, neither SB20358 nor SP600125 could antagonize this response to Δ 2-TGZ (Fig. 5A and B).

3.4. PPAR γ -independent expression of EGR1 does not require EGFR activation

We tested the possibility for EGFR to be involved in the PPAR γ -independent activation of *EGR1* in MCF7 cells. For this purpose, we used the EGFR tyrosine kinase inhibitors PD153035 or AG1478. At 5 μ M, these compounds totally inhibited ERK1/2 phosphorylation in MCF7 cells exposed to EGF (15 nM for 5 minutes) (Fig. 6A). We also observed that the exposure to EGF (15 nM) for 1 hour could increase *EGR1* mRNA level in MCF7 cells and that this effect did not occur in the presence of the EGFR antagonists (Fig. 6B). However, in our conditions, Δ 2-TGZ-induced *EGR1* mRNA expression was not blocked by the two EGFR tyrosine kinase inhibitors AG1478 and PD153035 (Fig. 6C). Our study

performed in MCF7 cells transfected with siRNA targeting EGFR confirmed the absence of a role of EGFR in the induction of *EGR1* mRNA expression and ERK phosphorylation after $\Delta 2$ -TGZ treatment (Fig. 6D).

3.5. PPAR γ -independent expression of *EGR1* in MDA-MB-231 cells

In order to determine whether the PPAR γ -independent expression of *EGR1* expression could be observed in other breast cancer cells, we studied its expression in the hormone-independent cell line MDA-MB-231. After 3 hours of treatment, $\Delta 2$ -TGZ was able to induce *EGR1* mRNA expression (Fig. 7). Then, we investigated whether the ERK1/2 pathway was involved in this event. A pretreatment with the ERK1/2 inhibitor U0126 (5 μ M) abolished *EGR1* mRNA expression induced by $\Delta 2$ -TGZ in MDA-MB-231 cells (Fig. 7). In contrast, the EGFR inhibitor AG1478 had no effect (Fig. 7). Thus, the PPAR γ -independent expression of *EGR1* is not restricted to MCF7 cells.

3.6. PPAR γ -independent expression of *EGR1* is mediated by Ca^{2+}

In order to determine whether calcium signaling could be involved in the PPAR γ -independent ERK1/2-mediated induction of *EGR1* expression, MCF7 cells were pretreated for 30 minutes with the Ca^{2+} chelator BAPTA-AM before their exposure to PPAR γ ligands (25 μ M). This treatment abolished the usual increase in *EGR1* mRNA level (Fig. 8A). ERK1/2 could not be activated in these conditions (Fig. 8A). Interestingly, we observed that in MCF7 cells, the Ca^{2+} ionophore A23187 also induced *EGR1* mRNA expression but with an earlier response than those usually observed with $\Delta 2$ -TGZ (Fig. 8B). Moreover, A23187 treatment also induced ERK1/2 activation before *EGR1* mRNA expression (2 minutes versus 15 minutes respectively) (Fig. 8C). This A23187-triggered *EGR1* induction was prevented in

the presence of the antagonist U0126 which also inhibited ERK1/2 phosphorylation (data not shown).

Then, we studied intracellular Ca^{2+} in MCF7 cells (Fig. 8D). In control cells exposed to DMSO no change in the basal level of Ca^{2+} was observed. In contrast, MCF7 cells exposed for 2 minutes to 25 μM TGZ showed a fast increase in intracellular calcium, $[\text{Ca}^{2+}]_i$, which disappeared as soon as cells were back in TGZ-free medium (Fig. 8D, upper panel). After recovery to basal level, a new exposure to TGZ induced again a rise in $[\text{Ca}^{2+}]_i$. An increase in $[\text{Ca}^{2+}]_i$ was also observed in response to 25 μM $\Delta 2$ -TGZ, showing that the calcium increase observed with TGZ was a PPAR γ -independent event (Fig. 8D, middle panel). However, after elimination of $\Delta 2$ -TGZ, cytosolic calcium decreased more slowly than after TGZ treatment. This rise in $[\text{Ca}^{2+}]_i$ did not occur in the presence of BAPTA-AM but it was still observed when $\Delta 2$ -TGZ was applied in a Ca^{2+} -free solution suggesting that a release from intracellular stores was involved, rather than an influx of external Ca^{2+} (Fig. 8D, middle and lower panels).

3.7. EGR1 is a mediator of $\Delta 2$ -TGZ-induced growth arrest

To test whether EGR1 is critical for the antiproliferative action of $\Delta 2$ -TGZ, we performed gene silencing in MCF7 cells. The suppression of EGR1 expression was confirmed by RT-PCR (Fig. 9A). In each experiment, at least 50% of *EGR1* mRNA expression was observed. In MCF7 cells transfected with Ctrl siRNA, after 24h treatment with 15 μM $\Delta 2$ -TGZ, the number of viable cells was 47% of those exposed to DMSO. When the cells were transfected with the *EGR1* siRNA, $\Delta 2$ -TGZ affected less efficiently MCF7 cells since viable cells were 61% of those exposed to DMSO (Fig. 9B).

4. Discussion

In this study, we show that *EGR1* is an early target gene of TGZ in MCF7 cells with a peak of expression after 3 hours of treatment. Such a transient induction of EGR1 expression was also observed in response to CGZ and 15d-PGJ₂. The expression of EGR1 protein was confirmed by Western blotting and by the delayed induction of *NAB2*, a well known EGR1 target gene [21]. EGR1 could be a mediator of PPAR γ ligand action since a transient stimulation of its expression has also been reported in other cell lines like human colorectal carcinoma cells HCT116 or activated T cells in response to TGZ or 15d-PGJ₂ respectively [10, 22].

Our results demonstrate that EGR1 expression is stimulated in breast cancer cell lines in a PPAR γ -independent manner. This was first suggested by the fact that RGZ was not able to induce EGR1 expression although it was the most potent PPAR γ agonist tested [10]. We confirmed the PPAR γ -independent mechanism by the use of the PPAR γ antagonist GW9662 and PPAR γ silencing. Furthermore, the TGZ inactive derivative Δ 2-TGZ was also able to stimulate EGR1 expression after 3 hours of treatment in both hormone-dependent (MCF7) and hormone-independent (MDA-MB-231) breast cancer cells. These results are consistent with data obtained in human colorectal carcinoma cells HCT116 [13]. Thus, EGR1 expression can be added to the increasing list of PPAR γ -independent effects of thiazolidinediones observed in cancer cell lines [9].

The activation of the MEK/ERK/ELK cascade is the classical pathway essential for enhanced EGR1 biosynthesis [23]. In MCF7 cells, we clearly demonstrated that a transient phosphorylation of ERK1/2 occurred early after TGZ, CGZ and 15d-PGJ₂ treatment whereas no change in ERK phosphorylation was observed in response to RGZ. A similar effect of

TGZ was previously described in MCF7 cells [24, 25], in porcine endothelial cells [26], and in the rat liver epithelial cell line GN4 [27, 28]. In GN4 cells, the phosphorylation of ERK was also stimulated by CGZ [27]. Consistent with our data, in astrocytes, CGZ and 15d-PGJ₂ stimulated ERK phosphorylation whereas RGZ was inefficient [29]. Interestingly, we found that ERK1/2 phosphorylation was also stimulated by Δ^2 -TGZ, demonstrating that it was a PPAR γ -independent event. This was previously reported in astrocytes not only with Δ^2 -TGZ but also with Δ^2 -CGZ [27]. We further show that this early activation is essential for EGR1 induction in MCF7 and MDA-MB-231 cells by the use of the MEK inhibitor U0126, like in HCT116 cells [13].

In parallel to ERK activation, thiazolidinediones are able to induce various MAPKs in different cell models [30]. For instance, in MCF7 cells, TGZ and TZD18 also activate p38 and c-jun N-terminal kinase (JNK) pathways [25, 31]. However, concerning the regulation of *EGR1* expression in MCF7 cells exposed to Δ^2 -TGZ, p38 and JNK pathways are likely not involved. Indeed, ERK1/2 phosphorylation inhibition is sufficient to completely block *EGR1* synthesis whereas JNK and p38 inhibitors have no effect. Consistent with our data, the p38 MAPK inhibitor PD169316 did not prevent *EGR1* induction by the retinoid AHPN in human lung carcinoma cells [32]. Similarly, in intestinal epithelial cells U0126 was able to block *EGR1* expression induced by sulindac sulfide whereas SP600125 and SB203580 were inefficient [33].

Previous studies suggested a connection between the EGFR and MAPK signaling by PPAR α and PPAR γ ligands [24, 34-36]. MCF7 and MDA-MB-231 cells expressed significant levels of EGFR protein [37]. However, in our study, although the EGFR antagonists AG1478 and PD153035 inhibited efficiently EGF-stimulated ERK phosphorylation and *EGR1* expression, they did not affect the stimulation of *EGR1* expression in case of Δ^2 -TGZ

treatment. Similarly, TGZ did not induce EGFR activation in rat liver epithelial cells GN4 [36].

MAPK phosphorylation is also often associated with an increase in $[Ca^{2+}]_i$. The Ca^{2+} -regulated protein kinase C can activate ERK through a RAF-dependent mechanism. Interestingly, TGZ and CGZ were shown to increase $[Ca^{2+}]_i$ in mouse ES cells, in rat liver epithelial cells GN4 as well as in normal urothelial cells [28, 38, 39]. In MCF7 cells, we show that TGZ triggers an immediate increase in cytosolic Ca^{2+} and that this event is also obtained in response to the PPAR γ -inactive compound Δ^2 -TGZ. This result is in accordance with the fact that both TGZ and CGZ trigger an increase in $[Ca^{2+}]_i$ not only in PPAR $\gamma^{+/+}$ but also in PPAR $\gamma^{-/-}$ mouse ES cells [38]. Moreover, we show for the first time that Ca^{2+} is essential for the activation of ERK1/2 and the expression of EGR1 by Δ^2 -TGZ, TGZ, CGZ, or 15d-PGJ₂ in MCF7 cells and MDA-MB-231. Interestingly, biosynthesis of EGR1 in MIN6 insulinoma cells treated with glucose, tolbutamide or KCl requires an elevation of Ca^{2+} [40].

We further observed that the increase in cytosolic Ca^{2+} occurred even when MCF7 cells were superfused in a Ca^{2+} -free solution containing EGTA, demonstrating liberation from intracellular stores rather than an influx from extracellular medium. This is in accordance with the effects described previously for TGZ and CGZ in mouse ES cells [38].

The roles of EGR1 in cancer development and response to therapies are ambiguous since EGR1 may either inhibit or stimulate cell growth depending on the stimulus and the cellular context. Many observations support the notion that EGR1 contributes to prostate cancer progression. The *EGR1* mRNA is highly expressed in prostate adenocarcinoma, compared with normal tissues [41]. In contrast, *EGR1* expression is absent or very weak in several human breast cancer cell lines and tissues compared to normal cells or tissues [17, 18].

We confirmed these data in the two breast cancer cell lines MCF7 and MDA-MB-231. We further show that induction of *EGR1* expression is partly involved in the anti-proliferative action of the thiazolidinedione $\Delta 2$ -TGZ. Indeed, *EGR1* depletion reduced by 14% the antiproliferative activity of $\Delta 2$ -TGZ on MCF7 cells. Similarly to our results, cellular sensibility to different therapeutic agents is modified after *EGR1* interference. For example, *EGR1* siRNA decreases the tolfenamic acid-induced apoptosis in the colorectal carcinoma cell line HCT-116 [42]. *EGR1* siRNA lowers by 15% cell death-induced by etoposide in osteosarcoma cells U2OS [43].

Concerning the events downstream of *EGR1*, it might be interesting to address the involvement of HSP70 and NF- κ B. Indeed, in lung fibroblasts, cigarette smoke water extracts induce an *EGR1*-dependent expression of HSP70 [44]. The latter can block the activation of the transcription factor NF κ B which is antiproliferative [45]. Moreover, the suppression of NF- κ B is involved in TGZ-induced inhibition of colon cancer cell growth [46].

Besides, *EGR1* induction was reported to occur in mouse embryonic fibroblasts exposed to the endoplasmic reticulum (ER)-stress inducer thapsigargin [47]. *EGR1* was also shown to play a role in thapsigargin-induced apoptosis in the melanoma cell line A375-C6 [48]. Since some PPAR γ ligands are known to trigger ER stress in breast cancer cell lines, the involvement of *EGR1* in the ER stress in breast cancer cells could be considered [31].

In summary, we provide evidence that TGZ, CGZ and 15d-PGJ₂ stimulate an early expression of *EGR1* in breast cancer cells in a PPAR γ -independent manner. This event requires a rise in $[Ca^{2+}]_i$, and the subsequent activation of ERK1/2 signaling pathway. We also show that *EGR1* participates in the PPAR γ -independent antiproliferative action. It will be

interesting to determine if thiazolidinediones also activate the Ca^{2+} /ERK/EGR1 pathway in non cancerous mammary epithelial cells or if this event is restricted to cancer cells.

Acknowledgments

We would like to thank SANOFI-AVENTIS for a studentship to Stéphane Salamone. We acknowledge Martine Chillet, Alexandra Kleinclauss, Brigitte Fernet, Sandrine Adach and François Dupire for technical assistance.

References

- [1] Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. *Pharmacol Rev* 2006; 58: 726-41.
- [2] Cheatham WW. Peroxisome proliferator-activated receptor translational research and clinical experience. *Am J Clin Nutr* 2010; 91: 262S-266S.
- [3] Blanquicett C, Roman J, Hart CM. Thiazolidinediones as anti-cancer agents. *Cancer Ther* 2008; 6: 25-34.
- [4] Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. *Clin Cancer Res* 2003; 9: 1-9.
- [5] Fenner MH, Elstner E. Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer. *Expert Opin Investig Drugs* 2005; 14: 557-68.
- [6] Kim KY, Kim SS, Cheon HG. Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells. *Biochem Pharmacol* 2006; 72: 530-40.

- [7] Kar R, Singha PK, Venkatachalam MA, Saikumar P. A novel role for MAP1 LC3 in nonautophagic cytoplasmic vacuolation death of cancer cells. *Oncogene* 2009; 28: 2556-68.
- [8] Zhou J, Zhang W, Liang B, Casimiro MC, Whitaker-Menezes D, Wang M, et al. PPARgamma activation induces autophagy in breast cancer cells. *Int J Biochem Cell Biol* 2009; 41: 2334-42.
- [9] Wei S, Yang J, Lee SL, Kulp SK, Chen CS. PPARgamma-independent antitumor effects of thiazolidinediones. *Cancer Lett* 2009; 276: 119-24.
- [10] Lecomte J, Flament S, Salamone S, Boisbrun M, Mazerbourg S, Chapleur Y, et al. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines. *Breast Cancer Res Treat* 2008; 112: 437-51.
- [11] Huang JW, Shiau CW, Yang YT, Kulp SK, Chen KF, Brueggemeier RW, et al. Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. *Mol Pharmacol* 2005; 67: 1342-8.
- [12] Colin C, Salamone S, Grillier-Vuissoz I, Boisbrun M, Kuntz S, Lecomte J, et al. New troglitazone derivatives devoid of PPARgamma agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines. *Breast Cancer Res Treat* 2010; 124: 101-10.
- [13] Baek SJ, Wilson LC, Hsi LC, Eling TE. Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. *J Biol Chem* 2003; 278: 5845-53.

- [14] Sukhatme VP, Cao XM, Chang LC, Tsai-Morris CH, Stamenkovich D, Ferreira PC, et al. A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. *Cell* 1988; 53: 37-43.
- [15] Swirnoff AH, Milbrandt J. DNA-binding specificity of NGFI-A and related zinc finger transcription factors. *Mol Cell Biol* 1995; 15: 2275-87.
- [16] Baron V, De Gregorio G, Krones-Herzig A, Virolle T, Calogero A, Urcis R, et al. Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo. *Oncogene* 2003; 22: 4194-204.
- [17] Huang JW, Shiau CW, Yang J, Wang DS, Chiu HC, Chen CY, et al. Development of small-molecule cyclin D1-ablative agents. *J Med Chem* 2006; 49: 4684-9.
- [18] Liu J, Liu YG, Huang R, Yao C, Li S, Yang W, et al. Concurrent down-regulation of Egr-1 and gelsolin in the majority of human breast cancer cells. *Cancer Genomics Proteomics* 2007; 4: 377-85.
- [19] Huang RP, Liu C, Fan Y, Mercola D, Adamson ED. Egr-1 negatively regulates human tumor cell growth via the DNA-binding domain. *Cancer Res* 1995; 55: 5054-62.
- [20] Boschi D, Tron GC, Lazzarato L, Chegaev K, Cena C, Di Stilo A, et al. NO-donor phenols: a new class of products endowed with antioxidant and vasodilator properties. *J Med Chem* 2006; 49: 2886-97.
- [21] Kumbrink J, Gerlinger M, Johnson JP. Egr-1 induces the expression of its corepressor nab2 by activation of the nab2 promoter thereby establishing a negative feedback loop. *J Biol Chem* 2005; 280: 42785-93.
- [22] Cippitelli M, Fionda C, Di Bona D, Lupo A, Piccoli M, Frati L, et al. The cyclopentenone-type prostaglandin 15-deoxy-delta 12,14-prostaglandin J2 inhibits CD95 ligand gene expression in T lymphocytes: interference with promoter activation via

peroxisome proliferator-activated receptor-gamma-independent mechanisms. *J Immunol* 2003; 170: 4578-92.

[23] Thiel G, Cibelli G. Regulation of life and death by the zinc finger transcription factor Egr-1. *J Cell Physiol* 2002; 193: 287-92.

[24] Friday E, Oliver R, 3rd, Welbourne T, Turturro F. Role of epidermal growth factor receptor (EGFR)-signaling versus cellular acidosis via Na⁺/H⁺ exchanger1(NHE1)-inhibition in troglitazone-induced growth arrest of breast cancer-derived cells MCF-7. *Cell Physiol Biochem* 2007; 20: 751-62.

[25] Yin F, Bruemmer D, Blaschke F, Hsueh WA, Law RE, Herle AJ. Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. *Oncogene* 2004; 23: 4614-23.

[26] Li X, Yang X, Xu Y, Jiang X, Nan F, Tang H. Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor gamma. *Cell Res* 2009; 19: 720-32.

[27] Gardner OS, Shiau CW, Chen CS, Graves LM. Peroxisome proliferator-activated receptor gamma-independent activation of p38 MAPK by thiazolidinediones involves calcium/calmodulin-dependent protein kinase II and protein kinase R: correlation with endoplasmic reticulum stress. *J Biol Chem* 2005; 280: 10109-18.

[28] Dewar BJ, Gardner OS, Chen CS, Earp HS, Samet JM, Graves LM. Capacitative calcium entry contributes to the differential transactivation of the epidermal growth factor receptor in response to thiazolidinediones. *Mol Pharmacol* 2007; 72: 1146-56.

[29] Lennon AM, Ramauge M, Dessouroux A, Pierre M. MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-Delta(12-14)-prostaglandin J(2) and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-

independent mechanisms involving reactive oxygenated species. *J Biol Chem* 2002; 277: 29681-5.

[30] Gardner OS, Dewar BJ, Graves LM. Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling. *Mol Pharmacol* 2005; 68: 933-41.

[31] Zang C, Liu H, Bertz J, Possinger K, Koeffler HP, Elstner E, et al. Induction of endoplasmic reticulum stress response by TZD18, a novel dual ligand for peroxisome proliferator-activated receptor alpha/gamma, in human breast cancer cells. *Mol Cancer Ther* 2009; 8: 2296-307.

[32] Sakaue M, Adachi H, Dawson M, Jetten AM. Induction of Egr-1 expression by the retinoid AHPN in human lung carcinoma cells is dependent on activated ERK1/2. *Cell Death Differ* 2001; 8: 411-24.

[33] Moon Y, Yang H, Kim YB. Up-regulation of early growth response gene 1 (EGR-1) via ERK1/2 signals attenuates sulindac sulfide-mediated cytotoxicity in the human intestinal epithelial cells. *Toxicol Appl Pharmacol* 2007; 223: 155-63.

[34] Orellana A, Holuigue L, Hidalgo PC, Faundez V, Gonzalez A, Bronfman M. Ciprofibrate, a carcinogenic peroxisome proliferator, increases the phosphorylation of epidermal-growth-factor receptor in isolated rat hepatocytes. *Eur J Biochem* 1993; 215: 903-6.

[35] Pauley CJ, Ledwith BJ, Kaplanski C. Peroxisome proliferators activate growth regulatory pathways largely via peroxisome proliferator-activated receptor alpha-independent mechanisms. *Cell Signal* 2002; 14: 351-8.

[36] Gardner OS, Dewar BJ, Earp HS, Samet JM, Graves LM. Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation. *J Biol Chem* 2003; 278: 46261-9.

- [37] Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, et al. The expression patterns of eR, pR, HeR2, cK5/6, eGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell Lines. *Breast Cancer: Basic and Clinical Research* 2010; 4: 35-41.
- [38] Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. *Cancer Res* 2001; 61: 6213-8.
- [39] Chopra B, Georgopoulos NT, Nicholl A, Hinley J, Oleksiewicz MB, Southgate J. Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels. *Cell Prolif* 2009; 42: 688-700.
- [40] Mayer SI, Thiel G. Calcium influx into MIN6 insulinoma cells induces expression of Egr-1 involving extracellular signal-regulated protein kinase and the transcription factors Elk-1 and CREB. *Eur J Cell Biol* 2009; 88: 19-33.
- [41] Gitenay D, Baron VT. Is EGR1 a potential target for prostate cancer therapy? *Future Oncol* 2009; 5: 993-1003.
- [42] Lee SH, Bahn JH, Choi CK, Whitlock NC, English AE, Safe S, et al. ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. *Mol Cancer Ther* 2008; 7: 3739-50.
- [43] Yu J, Baron V, Mercola D, Mustelin T, Adamson ED. A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells. *Cell Death Differ* 2007; 14: 436-46.
- [44] Li CJ, Ning W, Matthay MA, Feghali-Bostwick CA, Choi AM. MAPK pathway mediates EGR-1-HSP70-dependent cigarette smoke-induced chemokine production. *Am J Physiol Lung Cell Mol Physiol* 2007; 292: L1297-303.

[45] Gutierrez LL, Maslinkiewicz A, Curi R, de Bittencourt PI, Jr. Atherosclerosis: a redox-sensitive lipid imbalance suppressible by cyclopentenone prostaglandins. *Biochem Pharmacol* 2008; 75: 2245-62.

[46] Ban JO, Kwak DH, Oh JH, Park EJ, Cho MC, Song HS, et al. Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. *Chem Biol Interact* 2010; 188: 75-85.

[47] Liang SH, Zhang W, McGrath BC, Zhang P, Cavener DR. PERK (eIF2alpha kinase) is required to activate the stress-activated MAPKs and induce the expression of immediate-early genes upon disruption of ER calcium homeostasis. *Biochem J* 2006; 393: 201-9.

[48] Muthukkumar S, Nair P, Sells SF, Maddiwar NG, Jacob RJ, Rangnekar VM. Role of EGR-1 in thapsigargin-inducible apoptosis in the melanoma cell line A375-C6. *Mol Cell Biol* 1995; 15: 6262-72.

Footnotes

¹ Stephane Salamone present address: Unité de Chimie des Biomolécules (URA CNRS 2128), Institut Pasteur, 75724 Paris, France. stephane.salamone@pasteur.fr

This work was supported by grants of the “Université Henri Poincaré (BQR)”, of the “Conseil Régional de Lorraine”, of the “Association pour la Recherche sur le Cancer”, of the “Ligue Contre le Cancer”, of the “CPER” and of “FEDER”. Sarra Chbicheb was recipient of a grant of the “Ministère de l’enseignement supérieur et de la recherche”. Xiao Yao was recipient of a post-doctoral fellowship of the “Université Henri Poincaré and Conseil Régional de Lorraine”.

Figure legends

Fig. 1. Troglitazone induces *EGR1* expression. A, Time-dependent induction of *EGR1* mRNA in MCF7 cells exposed to 25 μ M TGZ (T) for the indicated times. Control cells were treated with 0.05% DMSO (D) or non-treated (NT). *EGR1* and the housekeeping gene *RPLPO* mRNA expression were analyzed by RT-PCR. The amplified products were analyzed by agarose gel electrophoresis. B, Dose-dependent induction of *EGR1* mRNA in MCF7 cells treated with decreasing doses of TGZ (T) for 3 hours. Control cells were treated with 0.05% DMSO (D) or non-treated (NT). *EGR1* mRNA was analyzed by RT-PCR and compared to the housekeeping gene *RPLPO*. The amplified PCR products were detected after agarose gel electrophoresis. C, Time-dependent induction of EGR1 protein (80 kDa) in MCF7 cells exposed to 25 μ M TGZ (T), 0.05% DMSO (D) or 20% fetal calf serum (FCS) for the indicated times. 20% FCS treatment was used as positive control. Nuclear extracts were prepared as described under “experimental procedures” and subjected to western blot analysis with anti-EGR1 antibody. D, Immunodetection of EGR1 (EGR1, middle panels) in MCF7 cells exposed to 25 μ M TGZ (T) or 20% FCS for 3 hours. Control cells were treated with 0.05% DMSO (D). The results of the counterstaining with Hoechst dye (left panels) as well as the merged pictures (right panels) are shown for each treatment. Bar represents 50 μ m and the magnification is identical for all pictures. E, Time-dependent induction of *EGR1* target gene *NAB2* in MCF7 cells exposed to 25 μ M TGZ (T) for the indicated times. Control cells were treated with 0.05% DMSO (D). *NAB2* and the housekeeping gene *RPLPO* expressions were analyzed at the mRNA level by RT-PCR. The amplified products were analyzed by agarose gel electrophoresis.

Fig. 2. Ciglitazone and 15d-PGJ₂ also stimulate the expression of *EGR1* and its target gene *NAB2*. A, Time-dependent induction of *EGR1* mRNA in MCF7 cells exposed to 25 μ M CGZ (C), 15d-PGJ₂ (P) and RGZ (R) for the indicated times. Control cells were treated with 0.05% DMSO (D, vehicle) or non-treated (NT). B, Induction of EGR1 protein (80kDa) in MCF7 cells exposed to 25 μ M CGZ (C), 15d-PGJ₂ (P), RGZ (R) or 0.05% DMSO (D) for 3 hours. Nuclear extracts were prepared as described under “experimental procedures” and subjected to western blot analysis using anti-EGR1 antibody. C, RT-PCR analysis of the expression of *NAB2* mRNA in MCF7 cells exposed for 6 and 9 hours to 25 μ M CGZ (C) and 15d-PGJ₂ (P), or 0.05% DMSO (D). The amplified products were detected after agarose gel electrophoresis and expressed relatively to the housekeeping gene *RPLPO*.

Fig. 3. *EGR1* expression is independent of PPAR γ activation. A, Absence of inhibition of *EGR1* induction in the presence of the PPAR γ antagonist GW9662. MCF7 cells were pretreated with 5 or 25 μ M GW9662 (GW) for 30 minutes before treatment with 25 μ M TGZ (T), CGZ (C) or 15d-PGJ₂ (P) for 3 hours. Control cells were treated with 0.05% DMSO (vehicle, D) or non-treated (NT). mRNA expression was analyzed by RT-PCR. B, TGZ-induced expression of *EGR1* mRNA after silencing of PPAR γ receptors by RNA interference. MCF7 cells were transiently transfected with double-strand siRNA targeting PPAR γ or control (Ctrl) siRNA. 48 hours after transfection, cells were exposed to 25 μ M TGZ (T) or 0.05% DMSO (D) for 3 hours. C, Expression of *EGR1* and its target gene *NAB2* following treatment with the PPAR γ inactive analogue of TGZ, Δ 2-TGZ. Cells were treated with 25 μ M Δ 2-TGZ (Δ 2T) or 0.05% DMSO (D) for the indicated times. mRNA expression was analyzed by RT-PCR. The amplified products were detected after agarose gel electrophoresis and expressed relatively to the housekeeping gene *RPLPO*. D, Induction of EGR1 protein (80kDa) in MCF7 cells exposed to 25 μ M TGZ (T), its inactive analogue, Δ 2-TGZ, (Δ 2T) or 0.05%

DMSO (D) for 3 hours. Nuclear extracts were prepared as described under “experimental procedures” and subjected to western blot analysis using anti-EGR1 antibody.

Fig. 4. The induction of *EGR1* expression depends on the activation of the ERK1/2 pathway. A, Changes in ERK1/2 phosphorylation were assessed in MCF7 cells after 25 μ M TGZ (T), CGZ (C), and 15d-PGJ₂ (P) treatment for the indicated times. Cells were harvested in 2X Laemmli buffer and total proteins were subjected to western blot analysis using anti-phospho-ERK1/2 antibody (P-ERK1/2). The blots were stripped and reprobed using antibody directed against total ERK1/2 (ERK1/2). B, A similar experiment was done in MCF7 cells after Δ 2-TGZ (Δ 2T) treatment for the indicated times. C, MCF7 cells were pretreated with 5 μ M U0126, a specific inhibitor of MEK1/2, for 30 minutes before treatment with 25 μ M TGZ (T), CGZ (C), 15d-PGJ₂ (P) for 15 minutes and 25 μ M Δ 2-TGZ (Δ 2T) for 30 minutes. Control cells were treated with 0.05% DMSO (vehicle). Phospho-ERK1/2 and total ERK1/2 were analyzed by western blot. D, MCF7 cells were pretreated with 5 or 25 μ M U0126, a specific inhibitor of MEK1/2, for 30 minutes before treatment with 25 μ M TGZ (T), CGZ (C), 15d-PGJ₂ (P) and Δ 2-TGZ (Δ 2T) for 3 hours. Control cells were treated with 0.05% DMSO (vehicle) or non-treated (NT). *EGR1* mRNA expression was analyzed by RT-PCR. The amplified products were detected after agarose gel electrophoresis and expressed relatively to the housekeeping gene *RPLPO*. E, Cells were pretreated with 5 μ M U0126 for 30 minutes before treatment with 25 μ M TGZ (T) for 3 hours. Nuclear extracts were prepared as described under “experimental procedures” and subjected to western blot analysis to detect the 80 kDa EGR1 protein. Control cells were treated with 0.05% DMSO (D, vehicle) or non-treated (NT).

Fig. 5. The induction of *EGR1* expression is independent on the activation of the p38 and JNK pathways. MCF7 cells were pretreated for 30 minutes with 10 μ M SB203580 (A) or SP600125 (B), specific inhibitors of p38 and JNK MAPK respectively, before treatment with 25 μ M Δ 2-TGZ (Δ 2T) for 3 hours. Control cells were treated with 0.05% DMSO (vehicle). *EGR1* mRNA expression was analyzed by RT-PCR. The amplified products were detected after agarose gel electrophoresis and expressed relatively to the housekeeping gene *RPLPO*.

Fig. 6. EGFR is not involved in the PPAR γ -independent expression of *EGR1*. A, Phospho-ERK1/2 and total ERK1/2 were analyzed by western blot. MCF7 cells were pretreated for 30 minutes with 5 μ M of the EGFR tyrosine kinase inhibitors PD153035 (PD) or AG1478 (AG) before treatment with 15 nM EGF for 5 minutes. Control cells were treated with 0.05% DMSO (D). B, *EGR1* mRNA expression induced by EGF and effects of different EGFR inhibitors. MCF7 cells were pretreated for 30 minutes with 5 μ M of the EGFR tyrosine kinase inhibitors PD153035 (PD) or AG1478 (AG) before treatment with 15 nM EGF for 1 hour. Control cells were treated with 0.05% DMSO (D). mRNA expression was analyzed by RT-PCR. The amplified products were detected after agarose gel electrophoresis and expressed relatively to the housekeeping gene *RPLPO*. C, *EGR1* mRNA expression in presence of different EGFR inhibitors. MCF7 cells were pretreated for 30 minutes with 5 μ M of the EGFR tyrosine kinase inhibitors PD153035 (PD) or AG1478 (AG) before treatment with 25 μ M Δ 2-TGZ (Δ 2T) for 3 hours. Control cells were treated with 0.05% DMSO (D). mRNA expression was analyzed by RT-PCR as described in B. D, Δ 2-TGZ-induced expression of *EGR1* mRNA and ERK phosphorylation after silencing of EGFR receptors by RNA interference. MCF7 cells were transiently transfected with double-strand siRNA targeting EGFR or control (Ctrl) siRNA. 48 hours after transfection, cells were exposed to 25 μ M Δ 2-TGZ (Δ 2T) or 0.05% DMSO (D). After 3 hours treatment, the expressions of *EGFR*,

EGR1 and *RPLPO* were analyzed at the mRNA level by RT-PCR. The amplified products were detected after agarose gel electrophoresis. After 30 minutes treatment, phospho-ERK1/2 and total ERK1/2 were analyzed by western blot.

Fig. 7. The PPAR γ -independent activation of *EGR1* expression is also observed in the hormone-independent breast cancer cell line MDA-MB-231. MDA-MB-231 cells were pretreated with 5 μ M U0126 (specific inhibitor of MEK1/2) or 5 μ M AG1478 (AG; EGFR tyrosine kinase inhibitor) for 30 minutes before treatment with 25 μ M Δ 2-TGZ (Δ 2T) for 3 hours. Control cells were treated with 0.05% DMSO (D, vehicle) or non-treated (NT). *EGR1* mRNA expression was analyzed by RT-PCR. The amplified products were detected after agarose gel electrophoresis. The housekeeping gene *RPLPO* was used as an internal control. The band intensities of *EGR1* were evaluated in terms of optical density arbitrary units and normalized with the *RPLPO* signal intensity. Data are presented in the histogram.

Fig. 8. *EGR1* expression and ERK1/2 phosphorylation depend on calcium mobilization.

A, Inhibition of *EGR1* mRNA expression and ERK1/2 phosphorylation in presence of the calcium chelator BAPTA-AM. MCF7 cells were pretreated with 50 μ M BAPTA-AM for 30 minutes before treatment with 25 μ M Δ 2-TGZ (Δ 2T), TGZ (T), CGZ (C) or 15d-PGJ2 (P) for 3 hours for *EGR1* expression detection. For ERK1/2 phosphorylation experiments, cells were treated with TGZ (T), CGZ (C) or 15d-PGJ2 (P) for 15 minutes and 30 minutes with Δ 2-TGZ (Δ 2T). Control cells were treated with 0.05% DMSO (D). *EGR1* mRNA expression was analyzed by RT-PCR. The amplified products were detected after agarose gel electrophoresis and expressed relatively to the housekeeping gene *RPLPO*. To detect changes in ERK1/2 phosphorylation status, cells were harvested in 2X Laemmli buffer and total proteins were subjected to western blot analysis using anti-phospho-ERK1/2 antibody (P-ERK1/2). The

blots were stripped and reprobed using antibody directed against total ERK1/2 (ERK1/2). B, Comparative study of *EGR1* mRNA expression induced by $\Delta 2$ -TGZ and the A23187 ionophore in MCF7 cells. Cells were treated with 25 μ M $\Delta 2$ -TGZ ($\Delta 2$ T) and 1 or 5 μ M A23187 ionophore for the indicated times. Control cells were treated with 0.05% DMSO (D). *EGR1* mRNA expression was analyzed by RT-PCR. The amplified products were detected after agarose gel electrophoresis and expressed relatively to the housekeeping gene *RPLPO*. C, Kinetic of ERK1/2 phosphorylation induced by the A23187 ionophore in MCF7 cells. Cells were treated with 1 μ M A23187 ionophore (A) for the indicated time and total proteins were subjected to western blot analysis as previously described. Control cells were treated with 0.05% DMSO (D). D, Cytoplasmic Ca^{2+} concentration was detected by the ratiometric fluorescent probe Fura-2. MCF7 cells were superfused with a saline solution and exposed during the indicated time to 0.05 % DMSO (upper panel), 25 μ M TGZ (upper panel) or 25 μ M $\Delta 2$ -TGZ (middle and lower panels). The effect of $\Delta 2$ -TGZ was also studied in MCF7 cells pretreated with 50 μ M of the calcium chelator BAPTA-AM (middle panel) as well as in calcium-free conditions (lower panel). The results are expressed as mean (black lines) $\pm$ s.e.m. (grey lines) of several measurements.

Fig. 9. *EGR1* plays a part in the antiproliferative action of $\Delta 2$ -TGZ. A, MCF7 cells were transiently transfected with double-strand siRNA targeting *EGR1* or control (Ctrl) siRNA. 48 hours after transfection, cells were exposed to 15 μ M $\Delta 2$ -TGZ ($\Delta 2$ T) or 0.05% DMSO (D) for 3 hours. mRNA expression for *EGR1* and *RPLPO* was analyzed by RT-PCR. The amplified products were detected after agarose gel electrophoresis. B, 28 hours after control (Ctrl) and *EGR1* siRNA transfection, cells were exposed to 15 μ M $\Delta 2$ -TGZ ($\Delta 2$ T) or 0.05% DMSO (D) for 24 hours. The number of viable cells was measured using the CellTiter-Glo™

Luminescent Cell Viability Assay. Results are given as mean $\pm$ s.e.m. of cell number
(arbitrary units) (n=5).

* Significantly different from Ctrl siRNA (p<0.01) using the unpaired t-Test.

TABLE 1. **siRNA sequences for PPAR γ , EGF receptors, and EGR1.** Sense and antisense oligonucleotides for each receptor gene were designed by Eurogentec (Angers, France). The sense (S) and antisense (AS) sequences for the siRNA duplexes are shown in the right column. *TT* did not belong to the target sequences and were added as 3' DNA over-hang. Control siRNA encodes random sequences with no homology to any known human genes.

Gene	Accession number		Target sequence (5'-3')	siRNA sequence (5'-3')
PPAR γ	NM_138712	Duplex 1	GTACCAAAGTGCAATCAAA	S:GUACCAAAGUGCAAUCAAATT AS:UUUGAUUGCACUUUGGUACTT
		Duplex 2	CAATCAGATTGAAGCTTAT	S:CAAUCAGAUUGAAGCUUAUTT AS:AUAAGCUUCAUUCUGAUUGTT
EGFR	NM_201283	Duplex 1	GCAGTGACTTTCTCAGCAA	S:GCAGUGACUUUCUCAGCAAATT AS:UUGCUGAGAAAGUCACUGCTT
		Duplex 2	GAGGAAATATGTACTACGA	S:GAGGAAAUUGUACUACGATT AS:UCGUAGUACAUAUUUCCUCCTT
EGR1	NM_001964.2		GTGACTGTTTGGCTTATA	S:GUGACUGUUUGGCUUAUAATT AS:UUAUAAGCCAAACAGUCACTT
Negative control	Eurogentec SR-CL000-005		none	non available

Accepted Manuscript

FIGURE 2

B **C**

FIGURE 5

A **B**

A **B** **C** **D**

FIGURE 7

FIGURE 8

FIGURE 1

FIGURE 2

FIGURE 3

FIGURE 4

A **B** **C** **D** **E**

FIGURE 5

A **B**

FIGURE 6

A **B** **C** **D**

FIGURE 7

FIGURE 8

FIGURE 9